Hold Sun Pharma; target of Rs 525: Sharekhan

December 06
09:25 2018

Sharekhan’s research report on Sun Pharma

Sun Pharma continues to remain surrounded by issues, the recent one being a whistle blower case filed with SEBI. Related party structure raises concerns among investors.


We downgrade our recommendation to Hold with downward revised PT of Rs. 525.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Related Articles